Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

BACKGROUND: In TEMPO 3:4, the vasopressin V2-receptor antagonist tolvaptan slowed kidney growth and resulted in function decline in autosomal dominant polycystic kidney disease (ADPKD) patients with relatively preserved kidney function. METHODS: Prospective, phase 3b, multi-center, randomized-withdr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Nephrol
Autors principals: Torres, Vicente E., Devuyst, Olivier, Chapman, Arlene B., Gansevoort, Ron T., Perrone, Ronald D., Ouyang, John, Blais, Jaime D., Czerwiec, Frank S., Sergeyeva, Olga
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497717/
https://ncbi.nlm.nih.gov/pubmed/28166521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000456087
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars